{"id":"W2591087106","doi":"10.1200/jco.2014.32.3_suppl.259","title":"Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; FOLFIRINOX; Internal medicine; Regimen; Performance status; Chemotherapy; Chemotherapy regimen; Cancer; Surgery; Irinotecan","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009659757,0.0001292189,0.00043472,0.0002872,0.0002703425,0.0003652016,0.0002069498,0.0002972565,0.00152151],"category_scores_gemma":[0.003181333,0.00009909327,0.0005229777,0.0002948312,0.0001898164,0.0003582626,0.0003709865,0.0003472761,0.0001813268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005166021,"about_ca_system_score_gemma":0.000557461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000613788,"about_ca_topic_score_gemma":0.001544053,"domain_scores_codex":[0.9995303,0.0001864834,0.00006130691,0.00008567644,0.0000703158,0.00006583559],"domain_scores_gemma":[0.9988748,0.0003531155,0.0004446852,0.000030658,0.00003655647,0.0002602269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06158442,0.001039916,0.8503412,0.0003778756,0.0002414126,0.0006093394,0.0002459122,0.0006908594,0.002908399,0.0001333805,0.001234094,0.08059324],"study_design_scores_gemma":[0.002722417,0.01568797,0.9715614,0.0001230051,0.0003922493,0.002709876,0.0003836087,0.00205855,0.0009642611,0.0002796758,0.003100052,0.00001695821],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980987,0.0008684569,0.00008383305,0.0001168892,0.00001030453,0.00007968304,0.0001642754,0.000003307409,0.0005745197],"genre_scores_gemma":[0.999383,0.0001455034,0.0001002193,0.00005611876,0.00001169626,0.00003580185,0.0002003908,5.56848e-7,0.00006674845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00152151,"threshold_uncertainty_score":0.005108654,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2640040517692418,"score_gpt":0.5254704340481197,"score_spread":0.2614663822788779,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}